Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.24 USD
-0.24 (-3.21%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $7.26 +0.02 (0.28%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Larimar Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 37 | 50 | 43 | 46 |
Income After Depreciation & Amortization | -42 | -37 | -50 | -43 | -46 |
Non-Operating Income | 5 | 1 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 2 |
Pretax Income | -37 | -35 | -51 | -42 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -35 | -51 | -42 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -35 | -51 | -42 | -45 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -37 | -50 | -43 | -46 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | -1 |
Income After Depreciation & Amortization | -42 | -37 | -50 | -43 | -46 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.90 | 25.76 | 17.16 | 11.88 | 3.11 |
Diluted EPS Before Non-Recurring Items | -0.84 | -1.37 | -2.95 | -3.57 | -12.85 |
Diluted Net EPS (GAAP) | -0.84 | -1.37 | -2.95 | -3.57 | -14.65 |
Fiscal Year end for Larimar Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 24.60 | 16.74 | 14.16 | 10.34 | 9.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | -24.60 | -16.74 | -14.16 | -10.34 | -9.63 |
Non-Operating Income | 2.97 | 2.08 | 1.17 | 1.28 | 1.25 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.63 | -14.65 | -12.99 | -9.06 | -8.37 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.63 | -14.65 | -12.99 | -9.06 | -8.37 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.63 | -14.65 | -12.99 | -9.06 | -8.37 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 63.80 | 53.55 | 43.91 | 43.90 | 43.90 |
Diluted EPS Before Non-Recurring Items | -0.34 | -0.27 | -0.30 | -0.21 | -0.19 |
Diluted Net EPS (GAAP) | -0.34 | -0.27 | -0.29 | -0.21 | -0.19 |